Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $13.25 Consensus Target Price from Analysts

Key Points

• Analysts have given Voyager Therapeutics a consensus recommendation of "Buy", with seven analysts rating it as a buy and one issuing a strong buy recommendation.
• The company's stock has seen a 30% increase due to a successful deal with Novartis, and has a 12-month price target of $13.25 from analysts.
• Recent quarterly earnings showed a loss of ($0.57) EPS, falling short of expectations, with revenue of $5.20 million against an anticipated $9.50 million.

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned an average rating of "Buy" from the eight research firms that are covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $13.2471.

Separately, Wedbush reduced their price target on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th.

Hedge Funds Weigh In On Voyager Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN grew its stake in shares of Voyager Therapeutics by 3.7% in the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company's stock valued at $378,000 after purchasing an additional 2,400 shares during the period. Tower Research Capital LLC TRC lifted its holdings in Voyager Therapeutics by 133.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after buying an additional 3,077 shares in the last quarter. Privium Fund Management B.V. lifted its stake in shares of Voyager Therapeutics by 16.6% in the 2nd quarter. Privium Fund Management B.V. now owns 25,241 shares of the company's stock valued at $79,000 after purchasing an additional 3,596 shares during the period. Geode Capital Management LLC lifted its stake in shares of Voyager Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company's stock valued at $6,149,000 after purchasing an additional 4,729 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at $29,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Price Performance

VYGR traded down $0.05 during trading on Friday, reaching $3.38. 195,217 shares of the stock traded hands, compared to its average volume of 526,112. The stock has a market cap of $187.21 million, a price-to-earnings ratio of -1.82 and a beta of 0.90. Voyager Therapeutics has a fifty-two week low of $2.64 and a fifty-two week high of $8.27. The stock's 50-day simple moving average is $3.27 and its two-hundred day simple moving average is $3.46.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.09). The firm had revenue of $5.20 million for the quarter, compared to analyst estimates of $9.50 million. Voyager Therapeutics had a negative net margin of 253.49% and a negative return on equity of 37.65%. Research analysts anticipate that Voyager Therapeutics will post -0.91 earnings per share for the current fiscal year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.